Home / Resource Library / Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe

Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe

Study examined pirtobrutinib for treatment of relapsed MCL.